Capricor Therapeutics to Participate in the Cantor Fitzgerald Rare Orphan Disease Summit

Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases, announced today that Dr. Linda Marbán, CEO of Capricor, will participate in a panel discussion at the virtual Cantor Fitzgerald Rare Orphan Disease Summit on March 30, 2022. Please see additional panel details below:

Cantor Fitzgerald Rare Orphan Disease Summit (Virtually March 29-30)

• Title: Cell Therapy: How the Definition Has Expanded with Time and the Potential Applications for Rare Diseases
• Panelist: Dr. Linda Marbán, CEO of Capricor
• Date: March 30, 2022
• Time: 4:00 p.m. ET

If you have interest in participating in the Cantor Virtual Rare Orphan Disease Summit, please reach out to your Cantor Fitzgerald representative.

About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a biotechnology company focused on developing transformative cell and exosome-based therapeutics and vaccines for treating and preventing a broad spectrum of diseases. Capricor`s lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in clinical development for treating Duchenne muscular dystrophy and the cytokine storm associated with COVID-19. Capricor is also developing its exosome technology as a next-generation therapeutic platform. The Company’s current focus is on developing exosomes capable of delivering nucleic acids, including mRNA as well as proteins, to treat or prevent a variety of diseases.